Varenicline Dosing for Smoking Cessation
The standard varenicline dosing regimen is 0.5 mg once daily for days 1-3, then 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from week 2 through week 12, with treatment initiated 1-2 weeks before the target quit date 1, 2.
Standard Dosing Schedule
The FDA-approved titration schedule minimizes dose-dependent nausea while achieving therapeutic effect:
- Days 1-3: 0.5 mg once daily (morning)
- Days 4-7: 0.5 mg twice daily
- Week 2 through Week 12: 1 mg twice daily (target maintenance dose)
Take varenicline orally after eating with a full glass of water 2. This dosing approach is consistently recommended across multiple guidelines 1, 3, 4 and represents the most evidence-based regimen for maximizing quit rates.
Treatment Duration
A minimum 12-week course is recommended for the initial quit attempt 1. For patients who successfully quit after 12 weeks, an additional 12-week course (total 24 weeks) significantly improves long-term abstinence rates 1, 2. The relapse-prevention data show continuous abstinence rates of 70.5% with extended varenicline versus 49.6% with placebo at 24 weeks 5.
Therapy may be extended to 6 months to 1 year to promote continued cessation, though guidelines suggest attempting to avoid longer periods when possible 1.
Renal Impairment Adjustments
Dosing must be adjusted based on creatinine clearance:
- Mild to moderate renal impairment (CrCl ≥30 mL/min): No adjustment needed 2
- Severe renal impairment (CrCl <30 mL/min):
- Starting dose: 0.5 mg once daily
- Maximum dose: 0.5 mg twice daily if tolerated 2
- End-stage renal disease on hemodialysis: Maximum 0.5 mg once daily if tolerated 2
Renal function is the most clinically important factor affecting varenicline exposure, as the drug is almost exclusively excreted unchanged in urine with minimal hepatic metabolism 6, 7. Monitor renal function in elderly patients who are more likely to have decreased kidney function 2.
Special Populations and Considerations
No hepatic dose adjustment is required - varenicline does not undergo significant hepatic metabolism 2, 6.
Elderly patients: No age-based dose adjustment needed, but assess renal function as elderly smokers may have age-related decline in kidney function 2, 8.
Flexible dosing for tolerability: If patients cannot tolerate adverse effects (particularly nausea), consider temporary or permanent dose reduction 2. Evidence suggests that lower doses (averaging 1.3 mg/day) can achieve abstinence rates >40% at 12 weeks while minimizing dose-dependent side effects 9. One study found equivalent 1-year abstinence rates (46.5% vs 46.4%) between 1 mg twice daily and 0.5 mg twice daily regimens 10.
Alternative Quit Approaches
Gradual reduction approach: For patients unable or unwilling to quit abruptly, varenicline can be started with a goal to reduce smoking by 50% within the first 4 weeks, another 50% in the next 4 weeks, and complete abstinence by 12 weeks. Continue treatment for an additional 12 weeks (total 24 weeks) 2.
Flexible quit date: Patients can begin varenicline and then quit smoking between days 8-35 of treatment rather than the standard 1-week pre-quit initiation 2.
Critical Safety Monitoring
Monitor for neuropsychiatric adverse events including mood changes, depression, suicidal ideation, agitation, and unusual behavior 1, 2. Advise patients to stop varenicline immediately and contact healthcare provider if these symptoms occur 2. Note that the FDA has removed the black box warning for neuropsychiatric events based on the EAGLES trial showing no increased risk compared to nicotine patches or placebo 1, 3, 4.
Contraindications: Avoid in patients with brain metastases due to seizure risk 1.
Common side effects: Nausea is the most frequent adverse event (occurring in 16-42% of patients), is dose-dependent, and may require management especially during chemotherapy 1, 6, 5. Taking varenicline with food helps minimize nausea 4, 2.
Drug Interactions
Varenicline has minimal drug interactions due to near-exclusive renal clearance without significant CYP450 metabolism 6, 7. No clinically meaningful interactions occur with warfarin, digoxin, cimetidine, metformin, bupropion, or transdermal nicotine 6, 7.